Success Item Removed From Cart

Basket Summary
Close

Your Cart is Empty

Subtotal
$0
Sales Tax
$0
Total
$0
Back to browsing

Acute Lymphocytic Leukemia Cell Therapy Market Overview

The total market value for the 15M, which includes both cell therapies and established/traditional ALL therapies was $2.3 billion in 2021. The need for “off-the-shelf” products with lower costs and reduced infrastructure requirements raises the development of allogeneic agents thereby driving the market growth.

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Outlook, 2021-2031 ($ Billion)

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Outlook, 2021-2031 ($ Billion)

Buy the Full Report to Know More about the Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Forecast

Download A Free Report Sample

The ALL–cell therapies 15-market research report offers a comprehensive insight into the market through 2032. The report provides an overview of the disease including epidemiology, symptoms, diagnosis, disease management, countries where the disease is prevalent, and leading players associated with the market.

Market Size (2021) $2.3 billion
Forecast Period 2021-2031
Key Regions ·       APAC

·       Europe

·       Middle East

·       North America

Leading Players ·       Juventas Cell Therapy

·       Autolus Therapeutics

·       Gamida Cell

·       Gilead

·       Cellectis S.A.

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Dynamics

The first-line setting is well-served by chemotherapy with high use of stem cell transplants on relapse. This blocks the entry of cell therapies into the more lucrative settings, which is hampering the market growth. However, the inability to find a donor for stem cell transplants drives the need for stem cell replacement products such as NiCord and TRGFT-201, which will positively impact the ALL cell therapies 15-market growth in the coming years.

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Analysis by Treatment

  • The ABL1, RLF2, and JAK2 genes, among others, are implicated in several different translocations or other mutations. These are classified generally as Philadelphia chromosome (Ph)-like cytogenetics, which may respond to treatment with TKIs.
  • Novartis’s Kymriah and Gilead’s Tecartus are the only marketed cell therapy products approved for the treatment of ALL as of 2022.

Buy Full Report for More Insights into the Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Treatment

Download a Free Report Sample

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Segmentation by Regions

North America had the highest sales in 15MM in the ALL-cell therapies 15-market.

A few of the key regions in the market are APAC, Europe, Middle East, and North America.

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Analysis by Regions, 2021 (%)

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Analysis by Regions, 2021 (%)

Buy the Full Report for More Regional Insights into the Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market

Download A Free Report Sample

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market -Competitive Landscape

Hebei Senlang Biotechnology and Chongqing Precision Biotech are the leading sponsors of cell therapy trials in ALL.

A few of the major players in the Acute Lymphocytic Leukemia (ALL) – -cell therapies 15-market are:

  • Juventas Cell Therapy
  • Autolus Therapeutics
  • Gamida Cell
  • Gilead
  • Cellectis S.A.

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Analysis by Companies

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Analysis by Companies

Buy the Full Report to Know More about Companies in the Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market

Download A Free Report Sample

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Country Outlook (Value, $ Billion, 2021-2031)

  • APAC
  • Europe
  • Middle East
  • North America

Reasons to buy

  • Assess the disease epidemiology and 10-year patient-based forecast (PBF) across the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China) and identify the potential countries for growth opportunities within the ALL-cell therapy market.
  • Analyze the clinical and commercial landscapes of each indication, with pricing assumptions
  • Evaluate indication-specific unmet needs and competitive assessments by Class of Therapy
  • Identify the Likelihood of Approval Analysis for the most promising agents and Phase Transition Success Rate Analysis.
  • Identify key future players based on their Pipeline Strength.

FAQs

  • The total market value for the 15M, which includes both cell therapies and established/traditional ALL therapies was $2.3 billion in 2021.

  • North America held the highest sales in the ALL–cell therapies 15-market across the 8MM in 2021.

  • A few of the major players in the ALL–cell therapies 15-market are Juventas Cell Therapy, Autolus Therapeutics, Gamida Cell, Gilead, and Cellectis S.A. among others.

What our clients have to say

More Reports

View More Reports